Subclinical atherosclerosis and silent myocardial ischaemia in patients with type 2 diabetes: a protocol of a clinico-observational study by Prasad, D. S. et al.
Subclinical atherosclerosis and silent
myocardial ischaemia in patients
with type 2 diabetes: a protocol of a
clinico-observational study
D S Prasad,1 Zubair Kabir,2 K Revathi Devi,3 A K Dash,4 B C Das5
To cite: Prasad DS , Kabir Z,
Devi KR, et al. Subclinical
atherosclerosis and silent
myocardial ischaemia in
patients with type 2 diabetes:
a protocol of a clinico-
observational study. Open
Heart 2014;1:e000100.
doi:10.1136/openhrt-2014-
000100
Received 27 February 2014
Revised 15 May 2014
Accepted 24 May 2014
1Sudhir Heart Centre,
Berhampur, Odisha, India
2Department of Epidemiology
& Public Health, University
College Cork, Cork, Ireland
3Diabetes Clinic, Sudhir Heart
Centre, Berhampur, Odisha,
India
4Department of Pathology,
MKCG Medical College,
Berhampur, Odisha, India
5Department of Community
Medicine, Kalinga Institute of
Medical Sciences,
Bhubaneshwar, Odisha, India
Correspondence to
Dr D S Prasad;
sudhir_heartcare@hotmail.
com
ABSTRACT
Introduction: Atherosclerotic cardiovascular disease is
a significant modifiable complication in patients with
diabetes and subclinical atherosclerosis is considered a
surrogate marker of future vascular events. The
clustering of cardiometabolic-risk factors in patients
with diabetes and cardiovascular disease is
increasingly being recognised. Recent evidence
indicates that 20–50% of asymptomatic patients with
diabetes may have silent coronary heart disease.
However, the identification of subclinical
atherosclerosis and silent myocardial ischaemia in
patients with diabetes has been less well-explored,
especially in low-resource population settings where
cost-effective non-invasive clinical tools are available.
The objective of this study is to identify patients with
physician-diagnosed diabetes who are at risk of
developing future cardiovascular events measured as
subclinical atherosclerosis and silent myocardial
ischaemia in an urban population of Eastern India.
Methods and analysis: This is a cross-sectional
clinico-observational study. A convenience sampling
of approximately 350 consecutive patients with type 2
diabetes based on predefined inclusion and exclusion
criteria will be identified at an urban diabetes center.
This estimated sample size is based on an expected
prevalence of silent myocardial ischaemia of 25%
(± 5%), we computed the required sample size using
OpenEpi online software assuming an α level of 0.05
(95% CI) to be 289. On factoring 20% non-response
the estimated sample size is 350. Previously validated
questionnaire tools and well-defined clinical,
anthropometric and biochemical measurements will be
utilised for data collection. The two primary outcomes
—subclinical atherosclerosis and silent myocardial
ischaemia will be measured using carotid intima-media
thickness and exercise tolerance testing, respectively.
Descriptive and multivariate logistic regression
statistical techniques will be employed to identify ‘at
risk’ patients with diabetes, and adjusted for potential
confounders.
Ethics and dissemination: Ethical approval was
granted by the institutional review board of Kalinga
Institute of Medical Sciences, Bhubaneshwar, India.
Data will be presented at academic fora and published
in peer-reviewed journals.
INTRODUCTION
Diabetes rates are rapidly increasing in
South–East Asia, with India and rest of
South–East Asia bearing the major burden, 65
and 72 million, respectively, accounting for
about one-ﬁfth of all cases worldwide.1 Recent
urban population studies from India showed a
relatively high prevalence of diabetes2–4 and
other cardiometabolic risk factors such as
hypertension, central obesity and physical
inactivity across all socioeconomic groups.5 6
Earlier studies—the Multiple Risk Factor
Intervention Trial (MRFIT) and the United
Kingdom Prospective Diabetes Study (UKPDS)
—have clearly established the underlying link
between cardiometabolic risk factors and the
increased risk of cardiovascular events in
patients with diabetes. Recent evidence suggests
that targeting interventions at the clustering of
cardiovascular risk factors is more effective in
preventing macrovascular disease rather than
KEY MESSAGES
▸ South Asians apparently have a unique cardio-
metabolic risk profile especially in the context of
Diabetes disorder. However, there is limited
information on the clinical implications of
exploring such clustering of cardiometabolic risk
profile among Diabetes patients in South Asian
populations.
▸ This study protocol examines two clinical but
modifiable outcomes - Subclinical Atherosclerosis
and Silent Myocardial Ischemia in asymptomatic
Diabetes patients employing cost-effective non-
invasive diagnostic tools – carotid intima-media
thickness and exercise tolerance testing measure-
ments, respectively.
▸ The study findings will provide additional
insights into expanding the existing knowledge
base for policy planners to consider implement-
ing cost effective guidelines in resource scarce
health care settings for identifying ‘at risk’ dia-
betic patients.
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treatment of hyperglycaemia alone.7 Moreover, an incre-
ment in the prevalence of diabetes indirectly implicates an
escalating coronary risk, particularly when diabetes and cor-
onary heart disease (CHD) share common risk factors,8 9
thus conﬁrming earlier evidence,10 11 and also consistent
with most recent evidence.12 13 Therefore, it is important to
identify cardiometabolic risk factors within patients with
diabetes who may be potentially prone to future cardiovas-
cular events.
Furthermore, patients with diabetes have 2–4-fold
increased risk of macrovascular disease compared with
patients without diabetes, with CHD and stroke being
the most common causes of death in patients with dia-
betes.14 CHD has been observed to affect two to three
decades earlier in patients with diabetes as opposed to
individuals without diabetes. Progression of coronary
and peripheral vascular atherosclerosis is one of the
most frequent and chronic complications of diabetes
mellitus.15 Nevertheless, atherosclerotic cardiovascular
disease (CVD) is a signiﬁcant modiﬁable complication
of altered glucose metabolism that also leads to consid-
erable disease burden, increased health services use and
premature morbidity and mortality.16 17 However,
patients with diabetes are often asymptomatic with myo-
cardial ischaemia which is commonly seen in a later
stage when it becomes clinically manifest.18
The recent evidence indicates that 20–50% of patients
with asymptomatic diabetes have silent CHD.19 Once
CHD is symptomatic in diabetes, morbidity and mortality
are high and signiﬁcantly worse than in patients without
diabetes.18 Hence, the advancement made in detection
and treatment of CHD allows reconsidering the non-
invasive and cost-effective screening of subclinical athero-
sclerosis by quantitative measurements of carotid intima-
media thickness (CIMT)20 21 and silent myocardial
ischaemia by exercise stress testing18 22 for early cardio-
vascular risk analysis, thus facilitating an effective thera-
peutic intervention in patients with high-risk diabetes.
Consequently, such early warning signs may potentially
lead to a decline in CVD-related disability and death.
Therefore, it is vital to detect subclinical atherosclerosis
early to prevent future vascular events in patients with
diabetes, considering that CVD and diabetes share
common cardiometabolic risk factors. We aim to conduct
a risk-assessment study in an urban population in Eastern
India among patients with diabetes identiﬁed through
clinical assessment over a period of 3 months, with the
following two main study objectives:
1. To determine prevalence and to identify risk factors
for silent myocardial ischaemia in patients with asymp-
tomatic diabetes.
2. To assess if CIMT is a surrogate marker of future vas-
cular events in patients with diabetes.
METHODS AND ANALYSIS
Study design
A cross-sectional clinico-observational study.
Study setting
Berhampur Municipal Corporation, an important city of
Odisha state one of the underdeveloped regions of
Eastern India bordering an afﬂuent state of Andhra
Pradesh of Southern India. Therefore, the residents
here are a diverse mix of socioeconomic class, language,
faith and customs.
Study population
The study will be a clinic-based observational study on
350 consecutive patients with type 2 diabetes (Diabetes)
attending the diabetic clinic at Sudhir Heart Centre,
Berhampur, India, over a period of 3 months.
Inclusion/exclusion criteria
Inclusion criteria:
A. Patients with diabetes (based on WHO criteria).
B. Patients with diabetes on treatment (oral antidiabetic
agents or insulins).
C. Normal resting ECG.
Exclusion criteria:
A. Patients with diabetes and cerebrovascular events.
B. Patients with diabetes and cardiovascular events such
as CHD and congestive cardiac failure.
C. Patients with diabetes and chronic kidney disease.
Primary outcome measures
Silent myocardial ischaemia (based on exercise toler-
ance testing) and subclinical atherosclerosis (identiﬁed
through carotid ultrasound based quantitative intima-
media measurements of the carotid artery).
Estimated sample size
Current estimates of silent myocardial ischaemia in
patients with diabetes among South Asian populations
are less well-documented. Based on literature review,23
we assumed a prevalence of silent myocardial ischaemia
among patients with diabetes to be 25%. Based on this
prevalence (±5%), we computed the required sample
size using OpenEpi online software assuming an α level
of 0.05 (95% CI) to be 289. On factoring 20% non-
response the estimated sample size is 350.24 The present
study will be a sequel to our previous community-based
study for knowing the prevalence of diabetes and
impaired glucose tolerance (IGT) in the same locale.2 5
We will take adequate care to ensure good response rate
by explaining the recruited participants about the
importance of study to self and also to the community at
large.
Data collection
Previously validated questionnaire tool that was applied
to earlier studies will be used.5 In short, we will employ
the WHO stepwise approach for data collection.25
Demographic, socioeconomic and self-reported behav-
ioural information (smoking, alcohol, physical activity
and diet), objective measures of anthropometry (height,
weight, waist and hip circumferences), biochemical
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(plasma glucose, glycosylated haemoglobin, total choles-
terol, triglycerides, high-density lipoprotein (HDL) chol-
esterol (HDLC), uric acid and creatinine levels) and
ECG readings will also be obtained. Health conditions
will be documented based on self-reported history of
diabetes, hypertension and CVD (chest pain, heart
attack or stroke). Family history for all of the above con-
ditions will be collected.
Blood pressure
Blood pressure will be recorded in the sitting position in
both arms to the nearest 2 mm Hg using a mercury
sphygmomanometer. Two readings will be taken 5 min
apart, and the mean of two will be taken as the blood
pressure.
Anthropometric measurements
Height will be measured with a tape to the nearest centi-
metre. All the participants will be expected to stand ver-
tical with no shoes with their back against the wall, heels
together and eyes focused forward.
Weight will be considered with a traditional spring
balance that is kept on a concrete ﬂat surface. The scale
is checked every day and calibration will be carried out
with ‘known’ weights. Participants will be asked to wear
minimal clothing and weight will be recorded to the
nearest 0.5 kg.
Body mass index (BMI) will be considered using the
formula: observed weight divided by height squared
(kg/m²).
Waist circumference will be measured using a non-
stretchable measuring tape. All the participants will be
asked to stand upright in a comfortable pose with both
feet together on a horizontal surface. Waist girth will be
noted as the lowest horizontal girth between the costal
margins and the iliac crests at least respiration.
Hip circumference will be noted as the maximum circum-
ference at the level of the greater trochanter (the widest
portion of the hip) on both sides. Measurements will be
noted to the nearest centimetre.
Waist and hip ratio will be obtained by dividing the waist
circumference (cm) by the hip circumference (cm).
ECG
The suggested procedure for obtaining a resting ECG,
and the technical requirements for a suitable ECG are
elaborated in the reference manual for the Minnesota
code, and the same will be followed for all the partici-
pants.26 ECG changes suggestive of ST segment depres-
sion (Minnesota 4–1 to 4–2) or Q wave changes
(Minnesota codes 1–1–1 to 1–1–7) or T wave changes
(Minnesota codes 5–1 to 5–3) or (Minnesota code 7-1-1)
for complete left bundle branch block will be noted.27
Tread mill test
All the patients with diabetes included in the study, will
undergo an exercise tolerance testing under Bruce
protocol and will be separated into two groups
according to the positive or negative test results for pro-
vocable ischaemia. Planar or down-sloping ST segment
depression >1 mm is the generally dependable indicator
of exercise-induced ischaemia.28
1. No CHD: exercise stress test negative.
2. CHD: this group of patients having a positive exercise
tolerance test result will be labeled as having silent
ischaemia.
Carotid ultrasound
Quantitative measurements of CIMT by carotid ultra-
sound using the method as advised by the American
Society of Echocardiography.21 Intimal medial measure-
ments of the carotid artery are acknowledged as a stand-
ard of atherosclerosis in many clinical and
epidemiological studies and are extensively used.29 The
standard higher limit of intimal medial thickness is put
at 0.6 mm for these studies. An increment of about
0.1 mm or more is linked with an ampliﬁed risk of myo-
cardial infarct and/or cerebrovascular disease incidence
by about 2–6 times.30
Biochemical investigations
Biochemical investigations will be conducted on a sample
of blood collected from each participant with a
minimum 10 h of an overnight fast. All biochemical para-
meters will be performed using enzymatic kits as per the
following methods; plasma glucose by glucose oxidase-
peroxidase method,31 glycosylated haemoglobin32 by ion
exchange resin method, total cholesterol by cholesterol
oxidase (CHOD)/phenol-aminophenazone (PAP)
method,33 triglycerides by glycerol-3-phosphate oxidase/
PAP method34 and high density lipoprotein cholesterol
(HDLC) by polyethylene glycol/CHOD-PAP method,35
low-density lipoprotein (LDL) and very LDL will be calcu-
lated using formulae of Freidewald et al.36 37 Non-HDLC
will be calculated using the formula (total cholesterol
−HDLC). In addition other parameters such as uric
acid38 by uricase/PAP method, urea39 by modiﬁed
Berthelot method and creatinine40 by modiﬁed Jaffe’s
method will also be carried out.
Definitions of study variables
Diabetes mellitus
Deﬁnition and diagnosis of diabetes mellitus and inter-
mediate hyperglycaemia was based on the Report of a
WHO/International Diabetes Federation (IDF)
Consultation, Geneva.
Diabetes will be considered as those diagnosed by a
physician and are on oral hypoglycaemic agents/insulin
and/or those who had a fasting plasma glucose level of
126 mg/dL (≥7.0 mmol/L) or 2 h plasma glucose
≥200 mg/dL (11.1 mmol/L) and IGT as fasting plasma
glucose of <7.0 mmol/L (126 mg/dL) and 2 h plasma
glucose of ≥7.8 and <11.1 mmol/L (140 mg/dL and
200 mg/dL).41
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Microalbuminuria
An unusually augmented excretion rate of albumin in the
urine in the range of 30–299 mg/g creatinine is consid-
ered as microalbuminuria.42 It is frequently encountered
and known as a cardiovascular risk indicator in diabetic
populations. Microalbuminuria is supposed to be due to
underlying generalised endothelial dysfunction.
Hypertension
Hypertension: based on physician diagnosis and antihyper-
tensive treatment or systolic blood pressure ≥140 or dia-
stolic blood pressure ≥90 mm Hg.43 44
Dyslipidaemia
Dyslipidaemia: based on the Third Report of the
National Cholesterol Education Program (NCEP).45
Hypercholesterolaemia: serum cholesterol >200 mg/dL;
hypertriglyceridaemia: serum triglycerides >150 mg/dL;
low HDLC: males ≤40 mg/dL and females ≤50 mg/dL.
Metabolic syndrome
Diverse criteria have been put forward by several organi-
sations for deﬁning metabolic syndrome.46 We have
adopted the latest deﬁnition from a Joint Interim
Statement of international organisations such as
International Diabetes Federation; National Heart,
Lung, and Blood Institute; American Heart Association;
World Heart Federation; International Atherosclerosis
Society; and International Association for the Study of
Obesity47 and a Consensus Statement from Association
of Physicians of India.48 Presence of any three of the fol-
lowing ﬁve cardiometabolic risk factors is essential for
the diagnosis.
1. Waist circumference: males ≥90 cm and females
≥80 cm.
2. Hypertriglyceridaemia ≥150 mg/dL (1.7 mmol/L).
3. Low HDLC: males <40 mg/dL (1 mmol/L) and
females <50 mg/dL (1.3 mmol/L).
4. Systolic blood pressure ≥130 mm Hg and/or diastolic
blood pressure ≥85 mm HG or drug treatment for
hypertension.
5. Fasting blood sugar ≥100 mg/dL (5.6 mmol/L) or
drug treatment for diabetes mellitus.
Obesity/overweight
Obesity and overweight: based on the revised criteria spe-
ciﬁc for Asian/Paciﬁc populations. Value of BMI
≥23 kg/m² used to deﬁne overweight and ≥25 kg/m² to
deﬁne obese.49 50
Physical activity
Data on physical activity will be collected with questions
on job-related and leisure time activities and exercise
such as mode of transport to place of work, nature of
work, number of days and type of exercise per week.51
Fruit/vegetable intake
Consumption of fruit and vegetable will be ascertained.
Intake of <5 servings a day will be considered as inad-
equate fruit intake.52
Socioeconomic status
Socioeconomic status of an individual will be based on
educational status, occupation and per capita income.53
Smoking
Data on smoking status of individual participants will be
collected to categorise them as current, former and
never a smoker.5 Users of all types of tobacco products
(combustible and non-combustible) who smoked every
day or some days in the past 1 month will be considered
a current smoker; those who have smoked less than 100
cigarettes/combustible products in their lifetime will be
considered a non-smoker; a former smoker is one who
did not smoke at the time of the interview and has
stopped smoking more than a month ago.
Analysis
All statistical analysis will be carried out using SPSS soft-
ware. All continuous variables (including CIMT) will be
reported as means±SD. The prevalence rates of various
cardiovascular risk factors in patients with diabetes will
be given in percentages. The mean values and frequen-
cies of various risk factors (variables) will be studied in
the group as a whole and individually in the two sub-
groups, namely those with silent CHD and those without
CHD employing Students t test (for continuous vari-
ables) and Pearson’s chi-squared test (χ2) for categorical
variables. Signiﬁcant predictors of silent CHD will also
be estimated applying backward elimination of multivari-
ate logistic regression. Next, within the patients with
silent CHD, two risk groups (namely, high and low)
based on known cardiometabolic risk factors will be
compared and contrasted employing multivariate logistic
regression analyses. Finally, mean difference and 1-SD
difference in CIMT readings will be estimated to predict
subclinical atherosclerosis in patients with diabetes
employing multivariate logistic regression techniques
simultaneously adjusting for potential confounders.
Statistically signiﬁcance will be assumed at p<0.05.
Clinical and public health implications of the study
This proposed study has important clinical and public
health implications considering that diabetes is fast
emerging as an epidemic in low-income and
middle-income nations. First, a baseline risk pattern of
patients with diabetes who may be at risk of developing
macrovascular events in the future can be identiﬁed and
documented. Second, the unique nature of the study
population is an important piece of information, thus
complementing the existing body of evidence. Third,
the study ﬁndings will be a better clinical management
tool for identifying ‘at risk’ patients. Fourth, the study
ﬁndings can be reproducible in different population
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settings for consistency. Future research must include a
comprehensive analysis of patients with diabetes who
may be at risk of developing vascular events in the
future through longitudinal follow-up studies.
Strengths and limitations of the study
The main limitation of the present study is its cross-
sectional nature, thus precluding us from inferring a
causal relationship. Residual confounding because of
unknown and unmeasured confounder will be a meth-
odological issue in this study. Other study limitations
such as recall and measurement biases will be minimised
through the administration of previously validated ques-
tionnaire tools, trained interviewers and with the help of
calibrated diagnostic and anthropometric tools based on
well-deﬁned measurement criteria. However, the main
strength of this study is the uniqueness of the study
population and the diverse data collection ranging from
sociodemographic, dietary, anthropometric to biochem-
ical and clinical measurements.
Ethics and dissemination
The study will be in agreement with the Indian Council
of Medical Research guidelines on bioethics.54 The
study proposal was approved by the institutional review
board of Kalinga Institute of Medical Sciences,
Bhubaneshwar, India.
A written informed consent will be obtained from all
participants prior to the study. All observations will be
presented at regional, national and global fora and pub-
lished in peer-reviewed journals. All upcoming publica-
tions will pursue the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) cri-
teria.55 Patients and policymakers will be informed of
results through presentations and reports (technical and
non-technical). It is our hope that these ﬁndings will
inform clinical and public health service development
in a resource scarce healthcare setting.
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